Look back at pharma news in the week to May 8, 2020

10 May 2020

By Barbara Obstoj-Cardwell. Editor

Italy’s Menarini kicked off the May M&A news last week, announcing it would acquire USA-based Stemline Therapeutics, gaining access to an already approved drug for rare blood cancer, Elzonis. This was followed by Alexion agreeing a $1.41 billion takeover offer for Portola Pharmaceuticals, along with its clotting factor Andexxa. Meantime, US health technology assessor, the Institute for Clinical and Economic Review (ICER), has come up with two scenarios on fair pricing for COVID-19 treatment remdesivir from Gilead Sciences. On the regulatory front, the US Food and Drug Administration granted earlier-than-expected approval for Novartis and Incyte’s new lung cancer drug Tabrecta (capmatinib).

Menarini proves COVID-19 no barrier to deal-making

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK